UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000048111
Receipt number R000054833
Scientific Title Megaprosthetic reconstruction of distal femur with short residual proximal femur following resection of bone tumor: a systematic review
Date of disclosure of the study information 2022/06/20
Last modified on 2023/06/20 16:24:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Megaprosthetic reconstruction of distal femur with short residual proximal femur following resection of bone tumor: a systematic review

Acronym

Megaprosthetic reconstruction of distal femur with short residual proximal femur following resection of bone tumor: a systematic review

Scientific Title

Megaprosthetic reconstruction of distal femur with short residual proximal femur following resection of bone tumor: a systematic review

Scientific Title:Acronym

Megaprosthetic reconstruction of distal femur with short residual proximal femur following resection of bone tumor: a systematic review

Region

Japan Europe


Condition

Condition

bone tumor

Classification by specialty

Orthopedics

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate the risk of postoperative function and complications in patients with short residual proximal femur after resection of a distal femoral bone tumor, we performed a systematic review of studies reporting functional results and complications in patients with short residual proximal femur after reconstruction of a distal femoral bone tumor with custom-made megaprosthesis, APC and CPS implant.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

mechanical survival where the endpoint was set to implant removal for any reason

Key secondary outcomes



Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

1 years-old <=

Age-upper limit

99 years-old >=

Gender

Male and Female

Key inclusion criteria

Only studies reporting functional results and complications regarding megaprosthetic reconstruction of distal femur with short residual proximal femur following resection of bone tumor were included.

Key exclusion criteria

(1) Studies in which reconstruction was performed in patients without short residual proximal femurs were excluded. Studies that performed reconstruction in patients with short residual proximal femurs and did not specify both functional results and complications were also excluded. (2) Only English- and Japanese-language literature was included, with no restriction on the year of publication.

Target sample size



Research contact person

Name of lead principal investigator

1st name Shinji
Middle name
Last name Tsukamoto

Organization

Nara medical university

Division name

Department of Orthopaedic Surgery

Zip code

634-8521

Address

840, Shijo-cho, Kashihara-city Nara 634-8521, Japan

TEL

0744223051

Email

shinji104@mail.goo.ne.jp


Public contact

Name of contact person

1st name Shinji
Middle name
Last name Tsukamoto

Organization

Nara Medical University

Division name

Department of Orthopaedic Surgery

Zip code

634-8521

Address

840, Shijo-cho, Kashihara-city Nara 634-8521, Japan

TEL

0744223051

Homepage URL


Email

shinji104@mail.goo.ne.jp


Sponsor or person

Institute

Nara medical university

Institute

Department

Personal name



Funding Source

Organization

Nara medical university

Organization

Division

Category of Funding Organization

Local Government

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nara Medical University

Address

840, Shijo-cho, Kashihara-city, Nara 634-8521, Japan

Tel

0744223051

Email

shinji104@mail.goo.ne.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 06 Month 20 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

70

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2022 Year 06 Month 18 Day

Date of IRB

2022 Year 06 Month 18 Day

Anticipated trial start date

2022 Year 06 Month 20 Day

Last follow-up date

2022 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Data collection and presentation
Two authors (ST and TM) independently selected the studies and extracted the data. In case of any disagreement, agreement was reached between the two or the third author was consulted. The following data were collected using the data collection sheet. (1) Basic data: author, year of publication, journal name, type of study, number of patients, age of patients, histology of tumor (2) Surgical indication, method of reconstruction, cement fixation, porous coating, time to full weight bearing, stem length of prosthesis, adjuvant chemotherapy, adjuvant radiotherapy, nonunion, aseptic loosening, implant breakage, fracture, infection, mechanical survival where the endpoint was set to implant removal for any reason, oncological outcome, Musculoskeletal Tumor Society (MSTS) score [19], postoperative follow-up period.

Data summary
Data extracted from the collected study data are summarized in Table 1 and 2. Table 3 summarized the time to full weight bearing, nonunion, aseptic loosening, implant breakage, fracture, infection, mechanical survival, MSTS score [19], and postoperative follow-up period for each reconstruction method (custom-made megaprosthesis, APC, and CPS implant). Because all the studies included in this review were non-randomized, data pooling (meta-analysis) was not appropriate, and thus, not performed.

Assessment of methodological quality
Two authors (ST and TM) independently assessed the quality of the included studies. When there was disagreement, agreement was reached between the two authors or by consulting a third author. Articles included in the final analysis were independently assessed according to the Risk of Bias Assessment tool for Non-randomized Studies (RoBANS tool) for assessing the quality of non-randomized studies in meta-studies [20].


Management information

Registered date

2022 Year 06 Month 20 Day

Last modified on

2023 Year 06 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000054833


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name